Knowles is no longer the consumer-microphone supplier that left Dover a decade ago. The company sold its Consumer MEMS Microphones unit to Syntiant at the end of 2024 and now lives as a specialty-components house selling high-reliability capacitors, radio-frequency filters, hearing-health microphones, and balanced-armature speakers into medtech, defense, industrial, and electrification programs. The second-quarter print tests whether that industrial mix is a finished transformation or a cycle still being priced as one. Shares near $35 already treat Precision Devices growth as structural rather than a defense-and-energy burst.
The most important recent development is not the beat itself. It is that Precision Devices grew across every named end market while the book-to-bill ratio, orders taken divided by shipments billed, stayed above one for a seventh straight quarter, and management then lifted full-year revenue growth into a double-digit band that sits above the organic range shown at the May 2025 Investor Day. A large energy-sector order is now shipping after a long qualification, and a multiyear defense radar award adds visibility past this year. That combination is how a mid-teens top line produced outsized earnings leverage.
The tension sits in the other half of the company. MedTech and Specialty Audio, the hearing-health franchise that still carries the Knowles brand into clinics, grew only modestly and remains guided to low-single-digit expansion. Cash from operations in the first half lagged the year-ago period as working capital rebuilt into the backlog, and an $83 million Syntiant preferred-stock stub still sits on the balance sheet with almost no cash return. A trailing earnings multiple above forty times leaves little room if Precision Devices simply reverts to the six-to-eight percent organic path management itself used as the five-year base case.
The next several quarters resolve the debate through backlog conversion rather than another portfolio move. If Precision Devices keeps a book-to-bill above one while Cornell Dubilier margins keep climbing toward the company average, the current multiple starts to look like payment for a real industrial compounder. If bookings fade once the energy order is fully in revenue and hearing health stays flat, the equity is paying a software-like price for a still-cyclical components book.